1-3 of 3
Marta Gil-Martin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

Ana Oaknin, Sharad A. Ghamande, Yuka Kasamatsu, Marta Gil-Martin, Juan Francisco Grau-Bejar, Carmen Garcia-Duran, Masashi Sato, Abdul Siddiqui, Surendra Pal Chaudhary, Yulia Vugmeyster, Kosei Hasegawa
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5): 975–983.
https://doi.org/10.1158/1078-0432.CCR-23-1829
Published: 01 March 2024
View article titled, Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer
Open the PDF for Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer in another window
Includes: Supplementary data
Journal Articles

Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

Beatriz Tavira, Teresa Iscar, Luis Manso, Ana Santaballa, Marta Gil-Martin, Yolanda García García, Margarita Romeo, Maria Iglesias, Ana de Juan Ferré, María Pilar Barretina-Ginesta, Aranzazu Manzano, Lydia Gaba, María Jesús Rubio, Carlos E. de Andrea, Antonio González-Martín
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 176–186.
https://doi.org/10.1158/1078-0432.CCR-23-0771
Published: 05 January 2024
View article titled, Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)
Open the PDF for Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study) in another window
Includes: Supplementary data
Journal Articles

Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

August Vidal, Clara Muñoz, María-José Guillén, Jemina Moretó, Sara Puertas, María Martínez-Iniesta, Agnés Figueras, Laura Padullés, Francisco J. García-Rodriguez, Mireia Berdiel-Acer, Miguel A. Pujana, Ramón Salazar, Marta Gil-Martin, Lola Martí, Jordi Ponce, David G. Molleví, Gabriel Capella, Enric Condom, Francesc Viñals, Dori Huertas, Carmen Cuevas, Manel Esteller, Pablo Avilés, Alberto Villanueva
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5399–5411.
https://doi.org/10.1158/1078-0432.CCR-12-1513
Published: 30 September 2012
View article titled, Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
Open the PDF for Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer in another window
Includes: Supplementary data